MarketsandMarkets Next - Gen Immuno Oncology Conference

WHAT TO EXPECT

Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumour microenvironment and Oncolytic Viruses

Exclusive conference to learn about antibodies, cellular therapy, and immune-checkpoint research under one roof.
Find out new case studies of immune-oncology projects in development.
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you.
Explore the latest platforms and technologies on the market for development.
Discuss the best tool for your research in immune oncology.
Share your work and achievements with your industry peers in the Poster Session

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Novel Targets and Therapeutic Approaches in Immuno-Oncology
Keynote Presentation – Biomarker considerations in Immuno-Oncology drug development Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche	09:00 - 09:35
Synthetic VHHs as building blocks for bi-specific T cell engagers Bill Eldridge, CEO, CSO, Isogenica	09:35 - 10:10
Drug Target Humanized Mouse Models for Evaluating Novel Therapeutics In Vivo James Jin, Vice President , Biocytogen	10:10 - 10:45
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:45 - 11:30
Anti-CD270 antibody checkpoint inhibitor for cancer treatment: Swing around patient’s CD270 immunosuppressive disadvantage Louis Boon, CSO , JJP Biologics	11:30 - 12:05
Navigating Multimodal Biomarker Data with the Veracyte Biopharma Atlas Valerie Balme, Associate Director, Business Development, Veracyte	12:05 - 12:40
Accelerating Discovery and Unveiling Cellular Insights: Accelerate Your Research with Revvity’s Advanced Immunoassay Solutions Fabienne Charrier Savournin, Life Sciences Technology Platform High Content Reagents Leader, Revvity Inc	12:40 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meeting	13:15 - 14:15
Neoadjuvant approaches and research in locally advanced melanoma Pier Francesco Ferrucci, Director, Tumour Biotherapy Unit, European Institute of Oncology	14:15 - 14:50
Understanding the effects of small molecule cancer therapies on the anti-tumour immune response Philip Beer, Chief Scientific Officer, Step Pharma	14:50 - 15:55
Evening Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:55 - 16:40
Antibody-drug conjugates (ADCs) against triple-negative breast cancer (TNBC) using pathway-specific inhibitors Anthony Cheung, Research Associate, King’s College London	16:40 - 17:15
Closing Remarks from the Chairperson	17:15 - 17:15
Drinks Reception & Networking	17:15 - 17:15
End of Day 1	17:15 - 17:15

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Combination Therapies, Tumour Micro-Environment and Personalized Medicine
Unlocking Immuno-Oncology Success: Elevating Industry Impact with Quality of Life endpoints in Cancer Clinical Trials Andrew Bottomley, Independent Outcomes Research Consultant, Bottomley Consulting Group	09:00 - 09:35
Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs Allan Stensballe, Associate Professor, Aalborg University	09:35 - 10:10
TBA Rick Kamps, Head Research Engineer in the Department of Toxicogenomics, Maastricht University	10:10 - 10:45
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:45 - 11:30
Small Molecule Cancer Immunotherapy via Allosteric Modulation of the Adenosine Pathway David Pejoski, CEO, Adoram Therapeutics	11:30 - 12:05
Targeting noncanonical epitope presented by HLA class I molecules in immuno-oncology Michele Mishto, Reader, King’s College London	12:05 - 12:40
Intravenous delivery of oncolytic virotherapy - a trojan horse approach Faith Howard, Co-Founder, NANOncolytics	12:40 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Autoimmune response against oxidative neoepitopes Ahuva Nissim, Professor, Antibody and Therapeutic Engineering, Queen Mary University of London	14:15 - 14:45
Novel therapies targeting solid tumours Ariel Marcotegui, Medical Science Liaison – Oncology, Amgen	14:45 - 15:20
Closing Remarks from the Chairperson	15:20 - 15:20
End of Conference	15:20 - 15:20

SPEAKERS

Anthony Cheung

Research Associate, King’s College London

Allan Stensballe

Associate Professor, Aalborg University

Faith Howard

Co-Founder, NANOncolytics

Louis Boon

CSO , JJP Biologics

James Jin

Vice President , Biocytogen

Michele Mishto

Reader, King’s College London

David Pejoski

CEO, Adoram Therapeutics

Bill Eldridge

CEO, CSO, Isogenica

Pier Francesco Ferrucci

Director, Tumour Biotherapy Unit, European Institute of Oncology

Senior Representative, Proteome Sciences

Fabienne Charrier Savournin

Life Sciences Technology Platform High Content Reagents Leader, Revvity Inc

Philip Beer

Chief Scientific Officer, Step Pharma

Ariel Marcotegui

Medical Science Liaison – Oncology, Amgen

Vaios Karanikas

Biomarker Experimental Medicine Leader, Oncology, Roche

Rick Kamps

Head Research Engineer in the Department of Toxicogenomics, Maastricht University

Andrew Bottomley

Independent Outcomes Research Consultant, Bottomley Consulting Group

Valerie Balme

Associate Director, Business Development, Veracyte

Ahuva Nissim

Professor, Antibody and Therapeutic Engineering, Queen Mary University of London

FAQ

What are the sponsorship opportunities available for the MarketsandMarkets Next-Gen Immuno Oncology Conference - EU Edition in Frankfurt, Germany?

We offer various sponsorship packages that cater to different levels of exposure and engagement. These opportunities range from platinum, gold, and silver sponsorships to customized packages based on your marketing objectives and budget.

As a sponsor, what benefits and exposure can we expect at the conference?

As a sponsor, you can expect benefits such as prominent branding in conference materials, website, and marketing collateral. Additionally, you will have the opportunity to address the audience during the event and network with key decision-makers and industry leaders.

How can our company maximize brand visibility and engagement with attendees during the event?

We provide numerous avenues to maximize your brand visibility, including logo placements, sponsored sessions, exhibition booths, and sponsored networking events. Engaging attendees through product demos and interactive displays is also encouraged.

Are there any specific sponsorship packages tailored to our companys marketing objectives and budget?

Yes, we understand the importance of aligning sponsorships with specific marketing goals. Our team can work with you to create a customized package that best suits your objectives and budget constraints.

Can we customize our sponsorship package to include specific promotional materials or activities?

Absolutely! We encourage sponsors to customize their packages with activities that resonate with their target audiences, such as branded merchandise, sponsored workshops, or exclusive sessions.

Is there a deadline to secure our sponsorship spot for the conference?

To ensure adequate planning and promotion, we recommend securing your sponsorship spot as early as possible. However, we will accommodate sponsorships until all available slots are filled.

What is the expected demographic and size of the audience attending the event?

The MarketsandMarkets Next-Gen Immuno Oncology Conference - EU Edition attracts a diverse audience, including industry experts, researchers, healthcare professionals, and key stakeholders. The expected size of the audience will be based on historical data and promotional efforts.